JP2009524670A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524670A5
JP2009524670A5 JP2008552395A JP2008552395A JP2009524670A5 JP 2009524670 A5 JP2009524670 A5 JP 2009524670A5 JP 2008552395 A JP2008552395 A JP 2008552395A JP 2008552395 A JP2008552395 A JP 2008552395A JP 2009524670 A5 JP2009524670 A5 JP 2009524670A5
Authority
JP
Japan
Prior art keywords
alkyl
saturated
heteroaryl
partially unsaturated
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008552395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524670A (ja
JP5236499B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/001956 external-priority patent/WO2007089512A1/en
Publication of JP2009524670A publication Critical patent/JP2009524670A/ja
Publication of JP2009524670A5 publication Critical patent/JP2009524670A5/ja
Application granted granted Critical
Publication of JP5236499B2 publication Critical patent/JP5236499B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008552395A 2006-01-27 2007-01-24 グルコキナーゼ活性化剤 Expired - Fee Related JP5236499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76317306P 2006-01-27 2006-01-27
US60/763,173 2006-01-27
PCT/US2007/001956 WO2007089512A1 (en) 2006-01-27 2007-01-24 Glucokinase activators

Publications (3)

Publication Number Publication Date
JP2009524670A JP2009524670A (ja) 2009-07-02
JP2009524670A5 true JP2009524670A5 (enExample) 2011-02-24
JP5236499B2 JP5236499B2 (ja) 2013-07-17

Family

ID=38109991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552395A Expired - Fee Related JP5236499B2 (ja) 2006-01-27 2007-01-24 グルコキナーゼ活性化剤

Country Status (9)

Country Link
US (1) US8022222B2 (enExample)
EP (1) EP1986645B1 (enExample)
JP (1) JP5236499B2 (enExample)
CN (1) CN101437512A (enExample)
AT (1) ATE539748T1 (enExample)
CA (1) CA2637172A1 (enExample)
ES (1) ES2378704T3 (enExample)
TW (1) TW200740804A (enExample)
WO (1) WO2007089512A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
CA2681695A1 (en) * 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
WO2009022179A2 (en) * 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT2209778E (pt) * 2007-09-21 2012-12-06 Array Biopharma Inc Derivados de piridin-2-il-amino-1,2,4-tiadiazole como activadores de glucoquinase para o tratamento de diabetes mellitus
SI2195312T1 (sl) 2007-10-09 2013-01-31 Merck Patent Gmbh Derivati piridina, uporabni kot aktivatorji glukokinaze
EP2235001B1 (en) 2008-01-23 2014-12-24 Bristol-Myers Squibb Company Process for preparing pyridinone compounds
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8293748B2 (en) 2008-10-02 2012-10-23 Respivert Ltd. p38 MAP kinase inhibitors
JPWO2010058846A1 (ja) * 2008-11-21 2012-04-19 アステラス製薬株式会社 4,6−ジアミノニコチンアミド化合物
JP5670912B2 (ja) 2008-12-11 2015-02-18 レスピバート・リミテツド p38MAPキナーゼ阻害剤
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
WO2011124930A1 (en) 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
WO2011124923A2 (en) 2010-04-08 2011-10-13 Respivert Limited Novel compounds
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
PL2730564T3 (pl) * 2010-11-19 2018-09-28 Ligand Pharmaceuticals Inc. Heterocykliczne aminy i ich zastosowania
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
KR20140051834A (ko) * 2011-03-09 2014-05-02 다이이찌 산쿄 가부시키가이샤 디피리딜아민 유도체
CN102786517B (zh) * 2011-05-18 2017-06-06 中国医学科学院药物研究所 Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物
JP5748210B2 (ja) * 2011-05-26 2015-07-15 日本化薬株式会社 複素環化合物の製造方法
PT2718270T (pt) * 2011-06-10 2022-07-29 Merck Patent Gmbh Composições e métodos para a produção de compostos de pirimidina e piridina com atividade inibidora de btk
WO2013035754A1 (ja) 2011-09-05 2013-03-14 中外製薬株式会社 クマリン誘導体の製造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013086397A1 (en) * 2011-12-08 2013-06-13 Array Biopharma Inc. Urea compounds as gka activators
WO2013173672A1 (en) 2012-05-18 2013-11-21 Array Biopharma Inc. Method for the preparation of thiadiazoles
JP6215338B2 (ja) * 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
WO2014159938A1 (en) * 2013-03-13 2014-10-02 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
CN104610143A (zh) * 2015-02-12 2015-05-13 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
CN107635981B (zh) * 2015-02-17 2020-08-04 中国科学院广州生物医药与健康研究院 用于诱导白色脂肪组织褐变的化合物和方法
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
CN107690429B (zh) * 2015-04-07 2022-02-25 Ela制药有限公司 用于治疗和/或预防细胞或组织坏死的组合物,其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶
EP3307702A4 (en) * 2015-06-11 2019-02-13 University of Pittsburgh - Of the Commonwealth System of Higher Education CHEMICAL P62 ZZ HEMMER
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
CA3039202A1 (en) * 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
KR102816656B1 (ko) * 2019-06-25 2025-06-02 인벤티스바이오 컴퍼니 리미티드 헤테로고리 화합물, 이의 제조방법 및 이의 사용방법
CN110898049B (zh) * 2019-11-29 2021-09-14 华中师范大学 二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂
CA3170411A1 (en) 2020-03-03 2021-09-10 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
WO2022147694A1 (en) * 2021-01-06 2022-07-14 Beijing Erai Therapeutics Co., Ltd. Aminoheteroaryl compounds and uses thereof
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023926T2 (de) * 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
CA2450562A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003078423A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
US20040023978A1 (en) * 2002-07-24 2004-02-05 Yu Ren Active salt forms with tyrosine kinase activity
PL375021A1 (en) * 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
JP2006507302A (ja) 2002-10-30 2006-03-02 メルク エンド カムパニー インコーポレーテッド キナーゼ阻害剤
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
JPWO2006008874A1 (ja) * 2004-05-21 2008-05-01 萬有製薬株式会社 アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤
WO2006076593A1 (en) * 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity
US20090105250A1 (en) * 2005-01-26 2009-04-23 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006258101A1 (en) 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases

Similar Documents

Publication Publication Date Title
JP2009524670A5 (enExample)
AU2019283921B2 (en) Indole carboxamide compounds useful as kinase inhibitors
CN105764514B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
JP2014506599A5 (enExample)
AU2015236428B2 (en) TrkA kinase inhibitors, compositions and methods thereof
JP2012528166A5 (enExample)
JP2017501234A5 (enExample)
TW200815427A (en) Organic compounds
JP7148660B2 (ja) 3-((ヘテロ-)アリール)-8-アミノ-2-オキソ-1,3-ジアザ-スピロ-[4.5]-デカン誘導体
JP2015531772A (ja) 融合二環式スルファモイル誘導体並びにb型肝炎の治療のための薬剤としてのその使用
JP2011507849A5 (enExample)
JP2009530410A5 (enExample)
JP2017512794A5 (enExample)
JP7627008B2 (ja) ピロール化合物
JP2017508766A5 (enExample)
JP2007510689A5 (enExample)
JP2015508402A (ja) 4,4−二置換−1,4−ジヒドロピリミジン、及びb型肝炎の処置のための医薬としてのその使用
JP2017512786A5 (enExample)
AU2017237930A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
JP2025515484A (ja) Kif18aを阻害するための化合物
JP2022534501A (ja) 三環式化合物
JP2020520925A5 (enExample)
US12344600B2 (en) c-Myc mRNA translation modulators and uses thereof in the treatment of cancer
JPWO2021020585A5 (enExample)
RU2008143388A (ru) Гетеросоединение